A practical reference to managing side effects associated with FDA-approved cancer immunotherapy drugs. Part One contains chapter-based overviews of immune checkpoint inhibitors in the clinic. Part Two is structured by common and uncommon toxicities that affect major organ sites throughout the body.
A practical reference to managing side effects associated with FDA-approved cancer immunotherapy drugs. Part One contains chapter-based overviews of immune checkpoint inhibitors in the clinic. Part Two is structured by common and uncommon toxicities that affect major organ sites throughout the body.Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Foreword Introduction Part 1: Immune Checkpoint Inhibitors in the Clinic Chapter One: Overview of Anti-CTLA-4 Agents: Ipilimumab and Tremilimumab 1. Daniel Hartman Johnson and Jianjun Gao Chapter Two: Overview of PD-1 and PD-L1 Inhibitors 2. Nikolaos Andreatos, Shailender Bhatia, and Petros Grivas Chapter Three: Indications and Toxicities of Immune Checkpoint Inhibitor Combinations 3. Lavinia Spain, Michael A. Postow, James Larkin, and Jeffrey Weber Part 2: Specific Immune Checkpoint Inhibitor Toxicities Chapter Four: General Principles of Immune-Related Toxicities 4. Osama E. Rahma and Patrick A. Ott Chapter Five: Dermatological Toxicities: Rash, Mucosal Irritation, and Pruritus 5. Jennifer Wu and Mario E. Lacouture Chapter Six: Musculoskeletal and Rheumatologic Toxicities 6. Noha Abdel-Wahab, Clifton O. Bingham III, and Maria Suarez-Almazor Chapter Seven: Immune-Related Gastrointestinal Toxicities 7. Hamzah Abu-Sbeih, Daniel Johnson, Yinghong Wang Chapter Eight: Pneumotoxicity Associated with Immune Checkpoint Blockades 8. Vickie R. Shannon Chapter Nine: Immune-Related Endocrinopathies Associated with Immune Checkpoint Inhibitors 9. Rajeev Sharma, Ha Nguyen, Ramona Dadu Chapter Ten: Neurologic Adverse Events and Neurologic Complications 10. Haroon Ahmad, Jasmin Jo, Elizabeth Gaughan, Camilo Fadul Chapter Eleven: Cardiovascular Toxicities Related to Immune Checkpoint Inhibitors 11. Pankit Vachhani, Igor Puzanov, Javid J. Moslehi Chapter Twelve: Renal Toxicities Associated with Immune Checkpoint Inhibitors 12. Ala Abudayyeh, Maen Abdelrahim, Laurence Albiges Chapter Thirteen: Hematologic Toxicities of Apparent Immune-Related Origins 13. George L. Chen, Caroline Robert, Alexander M. Lesokhin Chapter Fourteen: Ocular Toxicities Caused by Immune Dysregulation 14. Liliya Golas and Dimitra Skondra Chapter Fifteen: Safety and Regulation of Immune Checkpoint Inhibitors in Special Patient Populations 15. Douglas B. Johnson, Ryan Sullivan, Paolo A. Ascierto Chapter Sixteen: Cancer-Related Fatigue in Patients of Immune Checkpoint Inhibitor Therapy 16. Eric D. Hansen, Michelle Walter, Amy A. Case Chapter Seventeen: Cost Effectiveness and Financial Toxicity in New Cancer Therapies 17. Christine Kohn, Natalia Shcherbakova, Alberto J. Montero
Foreword Introduction Part 1: Immune Checkpoint Inhibitors in the Clinic Chapter One: Overview of Anti-CTLA-4 Agents: Ipilimumab and Tremilimumab 1. Daniel Hartman Johnson and Jianjun Gao Chapter Two: Overview of PD-1 and PD-L1 Inhibitors 2. Nikolaos Andreatos, Shailender Bhatia, and Petros Grivas Chapter Three: Indications and Toxicities of Immune Checkpoint Inhibitor Combinations 3. Lavinia Spain, Michael A. Postow, James Larkin, and Jeffrey Weber Part 2: Specific Immune Checkpoint Inhibitor Toxicities Chapter Four: General Principles of Immune-Related Toxicities 4. Osama E. Rahma and Patrick A. Ott Chapter Five: Dermatological Toxicities: Rash, Mucosal Irritation, and Pruritus 5. Jennifer Wu and Mario E. Lacouture Chapter Six: Musculoskeletal and Rheumatologic Toxicities 6. Noha Abdel-Wahab, Clifton O. Bingham III, and Maria Suarez-Almazor Chapter Seven: Immune-Related Gastrointestinal Toxicities 7. Hamzah Abu-Sbeih, Daniel Johnson, Yinghong Wang Chapter Eight: Pneumotoxicity Associated with Immune Checkpoint Blockades 8. Vickie R. Shannon Chapter Nine: Immune-Related Endocrinopathies Associated with Immune Checkpoint Inhibitors 9. Rajeev Sharma, Ha Nguyen, Ramona Dadu Chapter Ten: Neurologic Adverse Events and Neurologic Complications 10. Haroon Ahmad, Jasmin Jo, Elizabeth Gaughan, Camilo Fadul Chapter Eleven: Cardiovascular Toxicities Related to Immune Checkpoint Inhibitors 11. Pankit Vachhani, Igor Puzanov, Javid J. Moslehi Chapter Twelve: Renal Toxicities Associated with Immune Checkpoint Inhibitors 12. Ala Abudayyeh, Maen Abdelrahim, Laurence Albiges Chapter Thirteen: Hematologic Toxicities of Apparent Immune-Related Origins 13. George L. Chen, Caroline Robert, Alexander M. Lesokhin Chapter Fourteen: Ocular Toxicities Caused by Immune Dysregulation 14. Liliya Golas and Dimitra Skondra Chapter Fifteen: Safety and Regulation of Immune Checkpoint Inhibitors in Special Patient Populations 15. Douglas B. Johnson, Ryan Sullivan, Paolo A. Ascierto Chapter Sixteen: Cancer-Related Fatigue in Patients of Immune Checkpoint Inhibitor Therapy 16. Eric D. Hansen, Michelle Walter, Amy A. Case Chapter Seventeen: Cost Effectiveness and Financial Toxicity in New Cancer Therapies 17. Christine Kohn, Natalia Shcherbakova, Alberto J. Montero
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
USt-IdNr: DE450055826
